Keywords: Boehringer Ingelheim, Olodaterol, Tiotropium, Spiriva, COPD, Asthma exacerbation, ERS Congress, Respimat SMI

Boehringer reveals new data on olodaterol and tiotropium combo at ERS

Article | 04 September 2012

Print This

German family-owned drug major Boehringer Ingelheim for the first time presented data from a Phase II dose ranging study investigation ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in